Press Release
-
Early Warning for Breast Cancer Spread: EG BioMed Showcases Blood DNA Monitoring at AACR
Early Warning for Breast Cancer Metastasis: Molecular Clues from Limitations of Traditional Tests and New Possibilities Breast cancer is the most common cancer among women worldwide, accounting for over one-third of new female cancer cases. Despite advances in treatment, around 20% of early-stage patients still experience metastasis. Traditional markers like CA15-3 and CEA lack sensitivity…
-
EG BioMed Presents Early Pancreatic Cancer Detection at AACR with High-Potential DNA Methylation Markers
Early Detection of Pancreatic Cancer: Unlocking the Power of ZFP30 and ZNF781 Methylation Markers Gaps and Limitations in Pancreatic Cancer Diagnosis Pancreatic cancer is notoriously difficult to detect early, with most cases diagnosed at an advanced stage. Common tumor markers like CA19-9 and CEA often lack the sensitivity and specificity needed to guide timely treatment decisions. Research Advances In…
-
Patents & Global Certifications: EG BioMed’s DNA Methylation Blood Test Advances Early Cancer Detection
EG BioMed specializes in developing innovative blood-based cancer diagnostics centered on DNA methylation technology. The company has been awarded multiple patents both in the U.S. and internationally, including recent patents for early detection of pancreatic cancer (US 12,258,636 B2) and breast cancer (US 12,203,140 B2). These advancements are supported by globally recognized quality certifications—CLIA Laboratory…